Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy

被引：0

作者：

Michalaki, V.

Gennatas, S.

Gennatas, C. G.

机构：

[1] Univ Athens, Arete Hosp, Athens, Greece

[2] Univ Athens, Athens, Greece

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.5116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5116

引用

页数：1

共 50 条

[31] The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
Matsumoto, K
Katsumata, N
Yamanaka, Y
Yonemori, K
Kohno, T
Shimizu, C
Andoh, M
Fujiwara, Y
GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 412 - 416
[32] Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC)
McGonigle, K. F.
Muntz, H. G.
Vuky, J. L.
Paley, P. J.
Veljovich, D. S.
Gray, H. J.
Malpass, T. W.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[33] Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer
Rodriguez, M
Rose, PG
GYNECOLOGIC ONCOLOGY, 2001, 83 (02) : 257 - 262
[34] HEMATOLOGIC MARKERS OF SURVIVAL OUTCOME IN EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
Suprasert, P.
Jeerakornpassawat, D.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A523 - A523
[35] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
Chelariu-Raicu, Anca
Levenback, Charles F.
Slomovitz, Brian M.
Bodurka, Diane C.
Gershenson, David Marc
Coleman, Robert L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[36] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
Vacheresse, Genevieve MacAulay
Sabri, Elham
Domingo, Sheryl
Le, Tien
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
Vacheresse, Genevieve Macaulay
Le, Tien
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A194 - A194
[38] RESPONSE TO SUBSEQUENT PLATINUM-BASED CHEMOTHERAPY POST PARP INHIBITOR IN RECURRENT EPITHELIAL OVARIAN CANCER
Vacheresse, Genevieve Macaulay
Le, Tien
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A251 - A251
[39] Weekly Topotecan and Daily Thalidomide in Patients with Recurrent Epithelial Ovarian Cancer A Report of 2 Cases
Phippen, Neil T.
Leath, Charles A., III
JOURNAL OF REPRODUCTIVE MEDICINE, 2009, 54 (09) : 583 - 586
[40] Weekly topotecan as first-line treatment for recurrent or persistent epithelial ovarian cancer (EOC).
Safra, T
Menczer, J
Inbar, M
En-Shem, E
Glezerman, M
Grisaro, D
Ron, I
Levy, T
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 482S - 482S

← 1 2 3 4 5 →